Drug profile · INN
infigratinib
FEBSELTIQ
infigratinib (FEBSELTIQ) is a fibroblast growth factor receptor inhibitor.
EMA: application withdrawn Antineoplastic and immunomodulating agents (L01) L01E
Patents linked 0
Pipeline programs 11
News articles 0
Drug details — infigratinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 11
- Data quality
- 0.83
Quick answer
infigratinib (FEBSELTIQ) is a fibroblast growth factor receptor inhibitor.
Key facts
INN infigratinib
Brand FEBSELTIQ
Mechanism Fibroblast growth factor receptor inhibitor
Target Fibroblast growth factor receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01E
Mechanism of action
Fibroblast growth factor receptor inhibitor
Primary target: Fibroblast growth factor receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is infigratinib?
infigratinib (FEBSELTIQ) is a fibroblast growth factor receptor inhibitor.
What is the brand name for infigratinib?
FEBSELTIQ is a marketed brand name for infigratinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.